首页> 外文期刊>Prostate International >Twelve-year outcomes of prostate cancer after radical prostatectomy for T3 and/or positive margins managed with surveillance or salvage radiation therapy, based on risk groups
【24h】

Twelve-year outcomes of prostate cancer after radical prostatectomy for T3 and/or positive margins managed with surveillance or salvage radiation therapy, based on risk groups

机译:基于风险群体,在T3和/或阳性边缘治疗的T3和/或阳性边缘后,前列腺癌的12年成果,基于风险群体

获取原文
       

摘要

BackgroundTo assess 12-year outcomes on radical prostatectomy?with T3/positive margins, while categorizing patients into risk groups.MethodsFrom 2004 to 2007, 862 radical prostatectomy patients had T3/positive margins. Management included surveillance (54.8%), salvage radiation therapy (SRT) (36.8%), and primary androgen deprivation therapy (ADT) (8.5%). Freedom from biochemical failure, metastasis-free-survival (MFS), prostate cancer–specific survival (PCSS) were estimated using Kaplan-Meier. Multivariable analysis?established prognostic factors that affected PCSS, which were used to form risk groups. Subanalysis was performed on SRT patients.ResultsMedian follow-up was 12.1?years. T3b, Gleason score (GS), and detectable postoperative PSA independently lowered PCSS. Very–low-risk (VLR) were GS 6. Low-risk (LR) were GS 3?+?4 with T3a or positive margins, but undetectable postoperative PSA <0.1. High-risk (HR) were T3b with GS 7-10, or any GS 7-10 with T3a/b and positive margins, but undetectable PSA. Ultra–high-risk (UHR) were detectable PSA with GS 7-10. Median time to first salvage treatment for VLR, LR, HR, and UHR were 11.1, 10.8, 5.3, and 0.6?years, p?
机译:背景技术在激进的前列腺切除术上评估12年的结果?随着T3 /阳性边缘,同时将患者分类为风险群体。从2004年至2007年,862名自由基前列腺切除术患者具有T3 /阳性边缘。管理包括监测(54.8%),抢救辐射治疗(SRT)(36.8%)和原发性雄激素剥夺治疗(ADT)(8.5%)。使用Kaplan-Meier估计,从生化失败,转移存活(MFS),前列腺癌特异性生存(PCS)的自由。多变量分析?建立了影响PCS的预后因素,用于形成风险群体。对SRT患者进行了细分分析。结果媒体随访时间为12.1岁。 T3B,Gleason评分(GS)和可检测的术后PSA独立降低PCS。非常低风险(VLR)为GS 6.低风险(LR)具有T3A或阳性边缘的GS 3?4,但术后不可思来的PSA <0.1。高风险(HR)具有GS 7-10的T3B,或具有T3A / B和阳性边缘的任何GS 7-10,但不可检测的PSA。用GS 7-10可检测到超高风险(UHR)。为vlr,lr,hr和uhr的第一次挽救治疗的中值时间为11.1,10.8,5.3和0.6?年,p?<0.001。从VLR,LR,HR,UHR的生物化学失败的12年自由度为60.2%,52.9%,28.4%和0%,p?<0.001。对于12年的MFS,99.1%,97.8%,88.6%和63.6%,p?<0.001。对于12年的PC,99.5%,99.4%,93.5%和78.9%,p?<?0.001。对于317例SRT患者的细胞分析,10年的MFS为100.0%,97.0%,88.2%和84.6%,P?= 0.008. VLR / LR的结合要求使用监控或SRT作为初始管理产生优异的结果,在其中佐剂可以避免辐射治疗?或ADT加SRT。对于人力资源,早期的SRT或佐剂放射治疗可被认为是合理的,并且UHR患者可能会受益于ADT加上SRT。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号